Recent advances in targeted therapies in acute myeloid leukemia.

"Declarations Ethics approval and consent to participateThis is not applicable to this review. Consent for publicationThis is not applicable to this review. Competing interestsRSB receives consultancy fees from Alva10. CL serves on advisory boards for BMS, Jazz Pharma, Genentech, Novartis, Abbvie, Daiichi, Astellas, Macrogenics, Servier, and Taiho. Previous but not current speakers bureau: Astellas, Jazz KP has received research funding from AbbVie, Agios, Daiichi Sankyo, Millennium; served as an advisory board member for AbbVie, Astellas, Astra Zeneca, Boston BioMedical, Bristol-Myers Squibb, Celgene, Novartis, Jazz Pharmaceuticals, and Servier. Competing interests RSB receives consultancy fees from Alva10. CL serves on advisory boards for BMS, Jazz Pharma, Genentech, Novartis, Abbvie, Daiichi, Astellas, Macrogenics, Servier, and Taiho. Previous but not current speakers bureau: Astellas, Jazz KP has received research funding from AbbVie, Agios, Daiichi Sankyo, Millennium; served as an advisory board member for AbbVie, Astellas, Astra Zeneca, Boston BioMedical, Bristol-Myers Squibb, Celgene, Novartis, Jazz Pharmaceuticals, and Servier."

"Funding RSB is supported by the Hematopoiesis Training Program grant at the University of Pennsylvania (T32DK07780) from the National Institutes of Health (NIH)."